Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 466

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 2
Chunk 466
---
 5,584,724  
     —  
     5,612,782 

    Offering costs 
     —  
     —  

     (1,261,898) 
     —  
     (1,261,898)

    Net loss 
     —  
     —  
     —  
     —  
     —  
     (9,039,831) 
     (9,039,831)

    Balance at December 31, 2024 
     —  
     —  
     15,227,619  
    $106,593  
    $56,139,753  
    $(53,644,310) 
    $2,602,036 
  
    Balance 
     —  
     —  
     15,227,619  
    $106,593  
    $56,139,753  
    $(53,644,310) 
    $2,602,036 

The
accompanying notes are an integral part of these consolidated financial statements.

F-5

bioAffinity
Technologies, Inc.

Consolidated
Statements of Cash Flows

For
the Years Ended December 31, 2024 and 2023

    2024  
    2023 

    Cash flows from operating
    activities 

    Net loss 
    $(9,039,831) 
    $(7,937,011)
  
    Adjustments to reconcile
    net loss to net cash used in operating activities: 

    Depreciation and amortization 
     605,637  
     249,592 
  
    Stock-based compensation
    expense 
     989,681  
     748,823 

    Changes in operating
    assets and liabilities: 

    Accounts and other receivables 
     (327,530) 
     311,366 
  
    Inventory 
     (9,124) 
     (12,944)
  
    Prepaid expenses and
    other assets 
     (105,594) 
     214,402 
  
    Accounts payable 
     382,521  
     (14,501)
  
    Accrued expenses 
     248,911  
     362,012 
  
    Unearned